ICHD-3 beta
... headache has the characteristics of a primary headache (migraine, tension-type headache, cluster headache or one of the other trigeminal autonomic cephalalgias). When a pre-existing primary headache becomes chronic in close temporal relation to such a causative disorder, both the primary and the sec ...
... headache has the characteristics of a primary headache (migraine, tension-type headache, cluster headache or one of the other trigeminal autonomic cephalalgias). When a pre-existing primary headache becomes chronic in close temporal relation to such a causative disorder, both the primary and the sec ...
The International Classification of Headache Disorders, 3rd edition
... headache has the characteristics of a primary headache (migraine, tension-type headache, cluster headache or one of the other trigeminal autonomic cephalalgias). When a pre-existing primary headache becomes chronic in close temporal relation to such a causative disorder, both the primary and the sec ...
... headache has the characteristics of a primary headache (migraine, tension-type headache, cluster headache or one of the other trigeminal autonomic cephalalgias). When a pre-existing primary headache becomes chronic in close temporal relation to such a causative disorder, both the primary and the sec ...
Biotherapeutic Index
... Reciprocal relationships (arrows) between capillary system (capillaries, lymph vessels), ground substance, terminal autonomic axons, connective tissue cells (mast cells, defence cells, fibroblasts etc.) and parenchyma cells. Epithelial and endothelial cell groups rest on a basal membrane which medi ...
... Reciprocal relationships (arrows) between capillary system (capillaries, lymph vessels), ground substance, terminal autonomic axons, connective tissue cells (mast cells, defence cells, fibroblasts etc.) and parenchyma cells. Epithelial and endothelial cell groups rest on a basal membrane which medi ...
Those Who Suffer Much Know Much
... I first became aware of an obscure treatment that can halt or slow progression of Multiple Sclerosis (MS) and enhance quality of life for sufferers after receiving a health success story submission almost seven years ago, in 2003. Since then it’s become clear this obscure treatment can benefit a wid ...
... I first became aware of an obscure treatment that can halt or slow progression of Multiple Sclerosis (MS) and enhance quality of life for sufferers after receiving a health success story submission almost seven years ago, in 2003. Since then it’s become clear this obscure treatment can benefit a wid ...
lidocaine
... with the same buffered anesthetics. Infiltration with the unbuffered anesthetics was found to be 2.8 to 5.7 times more painful as their buffered counterparts. There was no significant difference detected in the time of onset or duration of anesthesia or the surface area of skin anesthetized ...
... with the same buffered anesthetics. Infiltration with the unbuffered anesthetics was found to be 2.8 to 5.7 times more painful as their buffered counterparts. There was no significant difference detected in the time of onset or duration of anesthesia or the surface area of skin anesthetized ...
View full report - Overcoming Multiple Sclerosis
... adopted it to benefit their patients: In Scotland, Dr Pat Crawley has been prescribing LDN successfully for years. He even traveled to New York to interview Dr Bihari for his own documentary. Dr Bob Lawrence in the UK and Dr Tom Gilhooly in Scotland have long been prescribing LDN, with success, to t ...
... adopted it to benefit their patients: In Scotland, Dr Pat Crawley has been prescribing LDN successfully for years. He even traveled to New York to interview Dr Bihari for his own documentary. Dr Bob Lawrence in the UK and Dr Tom Gilhooly in Scotland have long been prescribing LDN, with success, to t ...
Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma
... Monitoring Quality of Life ...............................................................................................61 ...
... Monitoring Quality of Life ...............................................................................................61 ...
American Academy of Neurology Headache Quality Measurement Set
... frequent symptoms seen in general practice.1 o Headache disorders affect more than 90% of all Americans.2 It has been estimated that 47% of the general adult population have headache at least once within last year.2 o Headache disorders are associated with personal and societal burdens of pain, disa ...
... frequent symptoms seen in general practice.1 o Headache disorders affect more than 90% of all Americans.2 It has been estimated that 47% of the general adult population have headache at least once within last year.2 o Headache disorders are associated with personal and societal burdens of pain, disa ...
(ARIA) 2008
... 3.6. Social class ......................................................................................................................................................................................................................38 4. Mechanisms ................................................... ...
... 3.6. Social class ......................................................................................................................................................................................................................38 4. Mechanisms ................................................... ...
101 SIGN British Guideline on the Management of Asthma
... (SIGN) agreed to jointly produce a comprehensive new asthma guideline, both having previously published guidance on asthma. The original BTS guideline dated back to 1990 and the SIGN guidelines to 1996. Both organisations recognised the need to develop the new guideline using explicitly evidence bas ...
... (SIGN) agreed to jointly produce a comprehensive new asthma guideline, both having previously published guidance on asthma. The original BTS guideline dated back to 1990 and the SIGN guidelines to 1996. Both organisations recognised the need to develop the new guideline using explicitly evidence bas ...
British Guideline on the Management of Asthma
... (SIGN) agreed to jointly produce a comprehensive new asthma guideline, both having previously published guidance on asthma. The original BTS guideline dated back to 1990 and the SIGN guidelines to 1996. Both organisations recognised the need to develop the new guideline using explicitly evidence bas ...
... (SIGN) agreed to jointly produce a comprehensive new asthma guideline, both having previously published guidance on asthma. The original BTS guideline dated back to 1990 and the SIGN guidelines to 1996. Both organisations recognised the need to develop the new guideline using explicitly evidence bas ...
guideline - Recommendations for the management of cough in adults
... Patients with cough frequently present to clinicians working in both primary and secondary care.1 2 Acute cough, which often follows an upper respiratory tract infection, may be initially disruptive but is usually self-limiting and rarely needs significant medical intervention. Chronic cough is ofte ...
... Patients with cough frequently present to clinicians working in both primary and secondary care.1 2 Acute cough, which often follows an upper respiratory tract infection, may be initially disruptive but is usually self-limiting and rarely needs significant medical intervention. Chronic cough is ofte ...
Pediatric Acne Management: Optimizing Outcomes
... Although acne vulgaris is most commonly seen in adolescents and young adults (85% of individuals between 12 and 24 years of age develop acne), it may be seen at any age. The disease frequently is seen in preadolescents, and its occurrence in children as young as 7 years of age is not rare. Untreated ...
... Although acne vulgaris is most commonly seen in adolescents and young adults (85% of individuals between 12 and 24 years of age develop acne), it may be seen at any age. The disease frequently is seen in preadolescents, and its occurrence in children as young as 7 years of age is not rare. Untreated ...
guideline - Recommendations for the management of cough in adults
... Patients with cough frequently present to clinicians working in both primary and secondary care.1 2 Acute cough, which often follows an upper respiratory tract infection, may be initially disruptive but is usually self-limiting and rarely needs significant medical intervention. Chronic cough is ofte ...
... Patients with cough frequently present to clinicians working in both primary and secondary care.1 2 Acute cough, which often follows an upper respiratory tract infection, may be initially disruptive but is usually self-limiting and rarely needs significant medical intervention. Chronic cough is ofte ...
Treatment for Glaucoma: Comparative Effectiveness Comparative Effectiveness Review Number 60
... studies that evaluated treatments with regard to their impact on visual impairment. We also found insufficient evidence comparing treatment versus no treatment on patient-reported outcomes. No studies addressed the possible link between intermediate outcomes (IOP, optic nerve structure, or visual fi ...
... studies that evaluated treatments with regard to their impact on visual impairment. We also found insufficient evidence comparing treatment versus no treatment on patient-reported outcomes. No studies addressed the possible link between intermediate outcomes (IOP, optic nerve structure, or visual fi ...
... in combating conditions for which there is not yet a cure, too. Medicines can help AIDS patients live longer, diagnostic tools such as mammography and ultrasounds can help doctors find tumors while they are treatable, and laser surgery techniques have made the most intricate, minute operations routi ...
Assessment Report - Word 8324 KB
... © Commonwealth of Australia 2014 This work is copyright. You may download, display, print and reproduce this material in unaltered form only (retaining this notice) for your personal, non-commercial use or use within your organisation. Apart from any use as permitted under the Copyright Act 1968, a ...
... © Commonwealth of Australia 2014 This work is copyright. You may download, display, print and reproduce this material in unaltered form only (retaining this notice) for your personal, non-commercial use or use within your organisation. Apart from any use as permitted under the Copyright Act 1968, a ...
2017 Final Rule for ESRD Facilities
... regulation to extend the appeals process to all types of actions taken by CMS for a supplier’s breach of contract, rather than limit an appeal for the termination of a competitive bidding contract. The rule also finalizes changes to the methodologies for adjusting fee schedule amounts for DMEPOS usi ...
... regulation to extend the appeals process to all types of actions taken by CMS for a supplier’s breach of contract, rather than limit an appeal for the termination of a competitive bidding contract. The rule also finalizes changes to the methodologies for adjusting fee schedule amounts for DMEPOS usi ...
MAGICAL MEDICINE: HOW TO MAKE AN ILLNESS DISAPPEAR
... • objective measurement of dysfunction 54,82-86 –deficits in working memory, concentration, information processing 87-95, autonomic function 96-98 (incl. neurally mediated hypotension and orthostatic intolerance) • abnormalities –regional brain hypoperfusion 99-106 by SPECT, white and gray matter ab ...
... • objective measurement of dysfunction 54,82-86 –deficits in working memory, concentration, information processing 87-95, autonomic function 96-98 (incl. neurally mediated hypotension and orthostatic intolerance) • abnormalities –regional brain hypoperfusion 99-106 by SPECT, white and gray matter ab ...
Property Flyer - Fuqua Development
... virologic suppression; highly active antiretroviral therapy (HAART), synonymous with cART, is no longer used and has been replaced by cART; the term ART has been used when referring to use of ARV drugs for HIV treatment more generally, including (mostly historical) use of one- or two-agent ARV regim ...
... virologic suppression; highly active antiretroviral therapy (HAART), synonymous with cART, is no longer used and has been replaced by cART; the term ART has been used when referring to use of ARV drugs for HIV treatment more generally, including (mostly historical) use of one- or two-agent ARV regim ...
GLOBAL STRATEGY FOR ASTHMA MANAGEMENT AND PREVENTION ® R
... National Jewish Medical & Research Center ...
... National Jewish Medical & Research Center ...
Abstracts - The Movement Disorder Society
... Ropinirole prolonged release is effective in reducing ‘‘off’’ time in patients with advanced Parkinson’s disease even at low doses F. Stocchi, L. Giorgi, N. Earl, R. Pahwa (Rome, Italy) ...
... Ropinirole prolonged release is effective in reducing ‘‘off’’ time in patients with advanced Parkinson’s disease even at low doses F. Stocchi, L. Giorgi, N. Earl, R. Pahwa (Rome, Italy) ...
CHAPTER 8 CEREBRAL CREATINE DEFICIENCY SYNDROMES
... drug-resistant seizures. Additional extra-pyramidal movement disorder and pathologic signal intensities in the basal ganglia on brain MRI are observed in the most severe cases. The clinical onset of the disease is between an age of four months to three years. Treatment with creatine monohydrate cons ...
... drug-resistant seizures. Additional extra-pyramidal movement disorder and pathologic signal intensities in the basal ganglia on brain MRI are observed in the most severe cases. The clinical onset of the disease is between an age of four months to three years. Treatment with creatine monohydrate cons ...
Management of multiple sclerosis
Several therapies for multiple sclerosis (MS) exist, although there is no known cure. Multiple sclerosis is a chronic inflammatory demyelinating disease that affects the central nervous system (CNS).The most common initial course of the disease is the relapsing-remitting subtype, which is characterized by unpredictable attacks (relapses) followed by periods of relative remission with no new signs of disease activity. After some years, many of the people who have this subtype begin to experience neurologic decline without acute relapses. When this happens it is called secondary progressive multiple sclerosis. Other, less common, courses of the disease are the primary progressive (decline from the beginning without attacks) and the progressive-relapsing (steady neurologic decline and superimposed attacks). Different therapies are used for patients experiencing acute attacks, for patients who have the relapsing-remitting subtype, for patients who have the progressive subtypes, for patients without a diagnosis of MS who have a demyelinating event, and for managing the various consequences of MS.The primary aims of therapy are returning function after an attack, preventing new attacks, and preventing disability. As with any medical treatment, medications used in the management of MS may have several adverse effects, and many possible therapies are still under investigation. At the same time different alternative treatments are pursued by many patients, despite the paucity of supporting, comparable, replicated scientific study.This article focuses on therapies for standard MS; borderline forms of MS have particular treatments that are excluded.